| Tanaz A Kermani, MD | |
|
2020 Santa Monica Blvd, Suite 540, Santa Monica, CA 90404-2023 | |
| (310) 582-6350 | |
| (310) 582-6352 |
| Full Name | Tanaz A Kermani |
|---|---|
| Gender | Female |
| Speciality | Rheumatology |
| Experience | 20 Years |
| Location | 2020 Santa Monica Blvd, Santa Monica, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720068448 | NPI | - | NPPES |
| 1720068448 | Other | CA | CCS PANELED |
| 1720068448 | Medicaid | CA | |
| 143411000 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | 47693 (Minnesota) | Secondary |
| 207RR0500X | Internal Medicine - Rheumatology | A118919 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Santa Monica - Ucla Med Ctr & Orthopaedic Hospital | Santa monica, CA | Hospital |
| Ronald Reagan Ucla Medical Center | Los angeles, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Regents Of The University Of California | 1355248584 | 1177 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilars of tumor necrosis factor (TNF)-alpha inhibitors stand to erode $9.6 billion in brand sales (Amgen's Enbrel, Abbott's Humira and Centocor Ortho Biotech/Schering-Plough's Remicade) in the U.S. and Europe (France, Germany, Italy, Spain and U.K.) by 2018. This use of TNF-alpha biosimilars will save healthcare systems in the U.S. and Europe $4 billion.
A new study examines data from Israel's vaccination campaign to assess the efficacy of the Pfizer-BioNTech mRNA vaccine across different demographics.
Tigris Pharmaceuticals, Inc., today announced enrollment of its first patient in a randomized Phase 2 clinical trial of AFP-464 with or without Faslodex in estrogen receptor (ER)-positive breast cancer patients.
More than eight of 10 leaders in health and health care policy believe states should be allowed to implement key provisions of the Affordable Care Act early with full federal support, ahead of the timeline outlined in the law.
In laboratory experiments, scientists have eliminated metastasis, the spread of cancer from the original tumor to other parts of the body, in melanoma by inhibiting a protein known as melanoma differentiation associated gene-9 (mda-9)/syntenin. More than 1 million cases of skin cancer are diagnosed each year in the U.S., and melanoma is the deadliest form.
› Verified 6 days ago
| Entity Name | The Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235107566 PECOS PAC ID: 1355248584 Enrollment ID: O20031223000439 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilars of tumor necrosis factor (TNF)-alpha inhibitors stand to erode $9.6 billion in brand sales (Amgen's Enbrel, Abbott's Humira and Centocor Ortho Biotech/Schering-Plough's Remicade) in the U.S. and Europe (France, Germany, Italy, Spain and U.K.) by 2018. This use of TNF-alpha biosimilars will save healthcare systems in the U.S. and Europe $4 billion.
A new study examines data from Israel's vaccination campaign to assess the efficacy of the Pfizer-BioNTech mRNA vaccine across different demographics.
Tigris Pharmaceuticals, Inc., today announced enrollment of its first patient in a randomized Phase 2 clinical trial of AFP-464 with or without Faslodex in estrogen receptor (ER)-positive breast cancer patients.
More than eight of 10 leaders in health and health care policy believe states should be allowed to implement key provisions of the Affordable Care Act early with full federal support, ahead of the timeline outlined in the law.
In laboratory experiments, scientists have eliminated metastasis, the spread of cancer from the original tumor to other parts of the body, in melanoma by inhibiting a protein known as melanoma differentiation associated gene-9 (mda-9)/syntenin. More than 1 million cases of skin cancer are diagnosed each year in the U.S., and melanoma is the deadliest form.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tanaz A Kermani, MD 2020 Santa Monica Blvd, Suite 540, Santa Monica, CA 90404-2023 Ph: (310) 582-6350 | Tanaz A Kermani, MD 2020 Santa Monica Blvd, Suite 540, Santa Monica, CA 90404-2023 Ph: (310) 582-6350 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilars of tumor necrosis factor (TNF)-alpha inhibitors stand to erode $9.6 billion in brand sales (Amgen's Enbrel, Abbott's Humira and Centocor Ortho Biotech/Schering-Plough's Remicade) in the U.S. and Europe (France, Germany, Italy, Spain and U.K.) by 2018. This use of TNF-alpha biosimilars will save healthcare systems in the U.S. and Europe $4 billion.
A new study examines data from Israel's vaccination campaign to assess the efficacy of the Pfizer-BioNTech mRNA vaccine across different demographics.
Tigris Pharmaceuticals, Inc., today announced enrollment of its first patient in a randomized Phase 2 clinical trial of AFP-464 with or without Faslodex in estrogen receptor (ER)-positive breast cancer patients.
More than eight of 10 leaders in health and health care policy believe states should be allowed to implement key provisions of the Affordable Care Act early with full federal support, ahead of the timeline outlined in the law.
In laboratory experiments, scientists have eliminated metastasis, the spread of cancer from the original tumor to other parts of the body, in melanoma by inhibiting a protein known as melanoma differentiation associated gene-9 (mda-9)/syntenin. More than 1 million cases of skin cancer are diagnosed each year in the U.S., and melanoma is the deadliest form.
› Verified 6 days ago
Irawan Susanto, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1223 16th St, Suite 3400, Santa Monica, CA 90404 Phone: 310-449-0939 Fax: 424-259-7790 | |
Louis Ravitz, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 2336 Santa Monica Blvd, Suite 207, Santa Monica, CA 90404 Phone: 310-828-9311 Fax: 310-453-8533 | |
Janet Winikoff, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 2001 Santa Monica Blvd Ste 860, Santa Monica, CA 90404 Phone: 310-828-3209 Fax: 310-828-5165 | |
Dr. Sean Dooley, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 2121 Santa Monica Blvd, Santa Monica, CA 90404 Phone: 323-829-8745 | |
Lorraine Anderson, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1245 16th St Ste 303, Santa Monica, CA 90404 Phone: 310-481-4646 Fax: 310-899-7599 | |
Dr. Colleen Lucy Channick, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1223 16th St Ste 3400, Santa Monica, CA 90404 Phone: 310-449-0939 | |
Carol Yukiko Nishikubo, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 2001 Santa Monica Blvd Ste 560w, Santa Monica, CA 90404 Phone: 310-453-5654 Fax: 310-453-6885 |